世界のAPOL1関与腎臓病市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global APOL1 Mediated Kidney Disease Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5595 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、APOL1関与腎臓病の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（小分子、遺伝子組み換え、核酸療法、その他）、用途別市場規模（慢性腎臓病、末期腎臓病）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・APOL1関与腎臓病の市場動向 ・企業の競争状況、市場シェア ・APOL1関与腎臓病の種類別市場規模と予測2016-2027（小分子、遺伝子組み換え、核酸療法、その他） ・APOL1関与腎臓病の用途別市場規模と予測2016-2027（慢性腎臓病、末期腎臓病） ・APOL1関与腎臓病の北米市場規模2016-2027（アメリカ、カナダ） ・APOL1関与腎臓病の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・APOL1関与腎臓病のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・APOL1関与腎臓病の中南米市場規模2016-2027（メキシコ、ブラジル） ・APOL1関与腎臓病の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Vertex Pharmaceuticals、Ionis Pharmaceuticals、Travere Therapeutics、ChemoCentryx、ZyVersa Therapeutics、GlaxoSmithKline、Novartis、Teva Pharmaceuticals） ・結論

APOL1 gene is a member of APOL gene family, which plays an important role in innate immunity, which is our body’s built-in defense system to fight threats. Some variations in APOL1 gene cause damage to parts within the kidney. Damage to parts that filter blood can lead to severe kidney disease or ultimately kidney failure. An example of such an indication is focal segmental glomerulosclerosis (FSGS), which is a type of kidney disease that can be caused by APOL1 gene variations.

Market Analysis and Insights: Global APOL1 Mediated Kidney Disease Market
The global APOL1 Mediated Kidney Disease market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global APOL1 Mediated Kidney Disease market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global APOL1 Mediated Kidney Disease market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global APOL1 Mediated Kidney Disease market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global APOL1 Mediated Kidney Disease market.

Global APOL1 Mediated Kidney Disease Scope and Market Size
APOL1 Mediated Kidney Disease market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global APOL1 Mediated Kidney Disease market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Small Molecule
Gene Modification
Nucleic Acid Therapies
Others

Segment by Application
Chronic Kidney Disease
End Stage Kidney Disease

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Vertex Pharmaceuticals
Ionis Pharmaceuticals
Travere Therapeutics
ChemoCentryx
ZyVersa Therapeutics
GlaxoSmithKline
Novartis
Teva Pharmaceuticals

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Small Molecule
1.2.3 Gene Modification
1.2.4 Nucleic Acid Therapies
1.2.5 Others
1.3 Market by Application
1.3.1 Global APOL1 Mediated Kidney Disease Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Chronic Kidney Disease
1.3.3 End Stage Kidney Disease
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global APOL1 Mediated Kidney Disease Market Perspective (2016-2027)
2.2 APOL1 Mediated Kidney Disease Growth Trends by Regions
2.2.1 APOL1 Mediated Kidney Disease Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 APOL1 Mediated Kidney Disease Historic Market Share by Regions (2016-2021)
2.2.3 APOL1 Mediated Kidney Disease Forecasted Market Size by Regions (2022-2027)
2.3 APOL1 Mediated Kidney Disease Industry Dynamic
2.3.1 APOL1 Mediated Kidney Disease Market Trends
2.3.2 APOL1 Mediated Kidney Disease Market Drivers
2.3.3 APOL1 Mediated Kidney Disease Market Challenges
2.3.4 APOL1 Mediated Kidney Disease Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue
3.1.1 Global Top APOL1 Mediated Kidney Disease Players by Revenue (2016-2021)
3.1.2 Global APOL1 Mediated Kidney Disease Revenue Market Share by Players (2016-2021)
3.2 Global APOL1 Mediated Kidney Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by APOL1 Mediated Kidney Disease Revenue
3.4 Global APOL1 Mediated Kidney Disease Market Concentration Ratio
3.4.1 Global APOL1 Mediated Kidney Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by APOL1 Mediated Kidney Disease Revenue in 2020
3.5 APOL1 Mediated Kidney Disease Key Players Head office and Area Served
3.6 Key Players APOL1 Mediated Kidney Disease Product Solution and Service
3.7 Date of Enter into APOL1 Mediated Kidney Disease Market
3.8 Mergers & Acquisitions, Expansion Plans

4 APOL1 Mediated Kidney Disease Breakdown Data by Type
4.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Type (2016-2021)
4.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2022-2027)

5 APOL1 Mediated Kidney Disease Breakdown Data by Application
5.1 Global APOL1 Mediated Kidney Disease Historic Market Size by Application (2016-2021)
5.2 Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America APOL1 Mediated Kidney Disease Market Size (2016-2027)
6.2 North America APOL1 Mediated Kidney Disease Market Size by Type
6.2.1 North America APOL1 Mediated Kidney Disease Market Size by Type (2016-2021)
6.2.2 North America APOL1 Mediated Kidney Disease Market Size by Type (2022-2027)
6.2.3 North America APOL1 Mediated Kidney Disease Market Size by Type (2016-2027)
6.3 North America APOL1 Mediated Kidney Disease Market Size by Application
6.3.1 North America APOL1 Mediated Kidney Disease Market Size by Application (2016-2021)
6.3.2 North America APOL1 Mediated Kidney Disease Market Size by Application (2022-2027)
6.3.3 North America APOL1 Mediated Kidney Disease Market Size by Application (2016-2027)
6.4 North America APOL1 Mediated Kidney Disease Market Size by Country
6.4.1 North America APOL1 Mediated Kidney Disease Market Size by Country (2016-2021)
6.4.2 North America APOL1 Mediated Kidney Disease Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe APOL1 Mediated Kidney Disease Market Size (2016-2027)
7.2 Europe APOL1 Mediated Kidney Disease Market Size by Type
7.2.1 Europe APOL1 Mediated Kidney Disease Market Size by Type (2016-2021)
7.2.2 Europe APOL1 Mediated Kidney Disease Market Size by Type (2022-2027)
7.2.3 Europe APOL1 Mediated Kidney Disease Market Size by Type (2016-2027)
7.3 Europe APOL1 Mediated Kidney Disease Market Size by Application
7.3.1 Europe APOL1 Mediated Kidney Disease Market Size by Application (2016-2021)
7.3.2 Europe APOL1 Mediated Kidney Disease Market Size by Application (2022-2027)
7.3.3 Europe APOL1 Mediated Kidney Disease Market Size by Application (2016-2027)
7.4 Europe APOL1 Mediated Kidney Disease Market Size by Country
7.4.1 Europe APOL1 Mediated Kidney Disease Market Size by Country (2016-2021)
7.4.2 Europe APOL1 Mediated Kidney Disease Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size (2016-2027)
8.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Type
8.2.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Type (2016-2021)
8.2.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Type (2022-2027)
8.2.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Type (2016-2027)
8.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Application
8.3.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Application (2016-2021)
8.3.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Application (2022-2027)
8.3.3 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Application (2016-2027)
8.4 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region
8.4.1 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2016-2021)
8.4.2 Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America APOL1 Mediated Kidney Disease Market Size (2016-2027)
9.2 Latin America APOL1 Mediated Kidney Disease Market Size by Type
9.2.1 Latin America APOL1 Mediated Kidney Disease Market Size by Type (2016-2021)
9.2.2 Latin America APOL1 Mediated Kidney Disease Market Size by Type (2022-2027)
9.2.3 Latin America APOL1 Mediated Kidney Disease Market Size by Type (2016-2027)
9.3 Latin America APOL1 Mediated Kidney Disease Market Size by Application
9.3.1 Latin America APOL1 Mediated Kidney Disease Market Size by Application (2016-2021)
9.3.2 Latin America APOL1 Mediated Kidney Disease Market Size by Application (2022-2027)
9.3.3 Latin America APOL1 Mediated Kidney Disease Market Size by Application (2016-2027)
9.4 Latin America APOL1 Mediated Kidney Disease Market Size by Country
9.4.1 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2016-2021)
9.4.2 Latin America APOL1 Mediated Kidney Disease Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size (2016-2027)
10.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type
10.2.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type (2016-2021)
10.2.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type (2022-2027)
10.2.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type (2016-2027)
10.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application
10.3.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application (2016-2021)
10.3.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application (2022-2027)
10.3.3 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application (2016-2027)
10.4 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country
10.4.1 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2016-2021)
10.4.2 Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Details
11.1.2 Vertex Pharmaceuticals Business Overview
11.1.3 Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.1.4 Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.1.5 Vertex Pharmaceuticals Recent Development
11.2 Ionis Pharmaceuticals
11.2.1 Ionis Pharmaceuticals Company Details
11.2.2 Ionis Pharmaceuticals Business Overview
11.2.3 Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.2.4 Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.2.5 Ionis Pharmaceuticals Recent Development
11.3 Travere Therapeutics
11.3.1 Travere Therapeutics Company Details
11.3.2 Travere Therapeutics Business Overview
11.3.3 Travere Therapeutics APOL1 Mediated Kidney Disease Introduction
11.3.4 Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.3.5 Travere Therapeutics Recent Development
11.4 ChemoCentryx
11.4.1 ChemoCentryx Company Details
11.4.2 ChemoCentryx Business Overview
11.4.3 ChemoCentryx APOL1 Mediated Kidney Disease Introduction
11.4.4 ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.4.5 ChemoCentryx Recent Development
11.5 ZyVersa Therapeutics
11.5.1 ZyVersa Therapeutics Company Details
11.5.2 ZyVersa Therapeutics Business Overview
11.5.3 ZyVersa Therapeutics APOL1 Mediated Kidney Disease Introduction
11.5.4 ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.5.5 ZyVersa Therapeutics Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline APOL1 Mediated Kidney Disease Introduction
11.6.4 GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis APOL1 Mediated Kidney Disease Introduction
11.7.4 Novartis Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.7.5 Novartis Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals APOL1 Mediated Kidney Disease Introduction
11.8.4 Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2016-2021)
11.8.5 Teva Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global APOL1 Mediated Kidney Disease Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Small Molecule
Table 3. Key Players of Gene Modification
Table 4. Key Players of Nucleic Acid Therapies
Table 5. Key Players of Others
Table 6. Global APOL1 Mediated Kidney Disease Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global APOL1 Mediated Kidney Disease Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global APOL1 Mediated Kidney Disease Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global APOL1 Mediated Kidney Disease Market Share by Regions (2016-2021)
Table 10. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global APOL1 Mediated Kidney Disease Market Share by Regions (2022-2027)
Table 12. APOL1 Mediated Kidney Disease Market Trends
Table 13. APOL1 Mediated Kidney Disease Market Drivers
Table 14. APOL1 Mediated Kidney Disease Market Challenges
Table 15. APOL1 Mediated Kidney Disease Market Restraints
Table 16. Global APOL1 Mediated Kidney Disease Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global APOL1 Mediated Kidney Disease Market Share by Players (2016-2021)
Table 18. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in APOL1 Mediated Kidney Disease as of 2020)
Table 19. Ranking of Global Top APOL1 Mediated Kidney Disease Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by APOL1 Mediated Kidney Disease Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players APOL1 Mediated Kidney Disease Product Solution and Service
Table 23. Date of Enter into APOL1 Mediated Kidney Disease Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global APOL1 Mediated Kidney Disease Market Size by Type (2016-2021) (US$ Million)
Table 26. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2016-2021)
Table 27. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global APOL1 Mediated Kidney Disease Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2016-2021)
Table 31. Global APOL1 Mediated Kidney Disease Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global APOL1 Mediated Kidney Disease Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America APOL1 Mediated Kidney Disease Market Size by Type (2016-2021) (US$ Million)
Table 34. North America APOL1 Mediated Kidney Disease Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America APOL1 Mediated Kidney Disease Market Size by Application (2016-2021) (US$ Million)
Table 36. North America APOL1 Mediated Kidney Disease Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America APOL1 Mediated Kidney Disease Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America APOL1 Mediated Kidney Disease Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe APOL1 Mediated Kidney Disease Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe APOL1 Mediated Kidney Disease Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe APOL1 Mediated Kidney Disease Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe APOL1 Mediated Kidney Disease Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe APOL1 Mediated Kidney Disease Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe APOL1 Mediated Kidney Disease Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific APOL1 Mediated Kidney Disease Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America APOL1 Mediated Kidney Disease Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America APOL1 Mediated Kidney Disease Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America APOL1 Mediated Kidney Disease Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America APOL1 Mediated Kidney Disease Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America APOL1 Mediated Kidney Disease Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa APOL1 Mediated Kidney Disease Market Size by Country (2022-2027) & (US$ Million)
Table 63. Vertex Pharmaceuticals Company Details
Table 64. Vertex Pharmaceuticals Business Overview
Table 65. Vertex Pharmaceuticals APOL1 Mediated Kidney Disease Product
Table 66. Vertex Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 67. Vertex Pharmaceuticals Recent Development
Table 68. Ionis Pharmaceuticals Company Details
Table 69. Ionis Pharmaceuticals Business Overview
Table 70. Ionis Pharmaceuticals APOL1 Mediated Kidney Disease Product
Table 71. Ionis Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 72. Ionis Pharmaceuticals Recent Development
Table 73. Travere Therapeutics Company Details
Table 74. Travere Therapeutics Business Overview
Table 75. Travere Therapeutics APOL1 Mediated Kidney Disease Product
Table 76. Travere Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 77. Travere Therapeutics Recent Development
Table 78. ChemoCentryx Company Details
Table 79. ChemoCentryx Business Overview
Table 80. ChemoCentryx APOL1 Mediated Kidney Disease Product
Table 81. ChemoCentryx Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 82. ChemoCentryx Recent Development
Table 83. ZyVersa Therapeutics Company Details
Table 84. ZyVersa Therapeutics Business Overview
Table 85. ZyVersa Therapeutics APOL1 Mediated Kidney Disease Product
Table 86. ZyVersa Therapeutics Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 87. ZyVersa Therapeutics Recent Development
Table 88. GlaxoSmithKline Company Details
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline APOL1 Mediated Kidney Disease Product
Table 91. GlaxoSmithKline Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 92. GlaxoSmithKline Recent Development
Table 93. Novartis Company Details
Table 94. Novartis Business Overview
Table 95. Novartis APOL1 Mediated Kidney Disease Product
Table 96. Novartis Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 97. Novartis Recent Development
Table 98. Teva Pharmaceuticals Company Details
Table 99. Teva Pharmaceuticals Business Overview
Table 100. Teva Pharmaceuticals Revenue in APOL1 Mediated Kidney Disease Business (2016-2021) & (US$ Million)
Table 101. Teva Pharmaceuticals Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global APOL1 Mediated Kidney Disease Market Share by Type: 2020 VS 2027
Figure 2. Small Molecule Features
Figure 3. Gene Modification Features
Figure 4. Nucleic Acid Therapies Features
Figure 5. Others Features
Figure 6. Global APOL1 Mediated Kidney Disease Market Share by Application: 2020 VS 2027
Figure 7. Chronic Kidney Disease Case Studies
Figure 8. End Stage Kidney Disease Case Studies
Figure 9. APOL1 Mediated Kidney Disease Report Years Considered
Figure 10. Global APOL1 Mediated Kidney Disease Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global APOL1 Mediated Kidney Disease Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global APOL1 Mediated Kidney Disease Market Share by Regions: 2020 VS 2027
Figure 13. Global APOL1 Mediated Kidney Disease Market Share by Regions (2022-2027)
Figure 14. Global APOL1 Mediated Kidney Disease Market Share by Players in 2020
Figure 15. Global Top APOL1 Mediated Kidney Disease Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in APOL1 Mediated Kidney Disease as of 2020
Figure 16. The Top 10 and 5 Players Market Share by APOL1 Mediated Kidney Disease Revenue in 2020
Figure 17. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2016-2021)
Figure 18. Global APOL1 Mediated Kidney Disease Revenue Market Share by Type (2022-2027)
Figure 19. North America APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America APOL1 Mediated Kidney Disease Market Share by Type (2016-2027)
Figure 21. North America APOL1 Mediated Kidney Disease Market Share by Application (2016-2027)
Figure 22. North America APOL1 Mediated Kidney Disease Market Share by Country (2016-2027)
Figure 23. United States APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe APOL1 Mediated Kidney Disease Market Share by Type (2016-2027)
Figure 27. Europe APOL1 Mediated Kidney Disease Market Share by Application (2016-2027)
Figure 28. Europe APOL1 Mediated Kidney Disease Market Share by Country (2016-2027)
Figure 29. Germany APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific APOL1 Mediated Kidney Disease Market Share by Type (2016-2027)
Figure 37. Asia-Pacific APOL1 Mediated Kidney Disease Market Share by Application (2016-2027)
Figure 38. Asia-Pacific APOL1 Mediated Kidney Disease Market Share by Region (2016-2027)
Figure 39. China APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America APOL1 Mediated Kidney Disease Market Share by Type (2016-2027)
Figure 47. Latin America APOL1 Mediated Kidney Disease Market Share by Application (2016-2027)
Figure 48. Latin America APOL1 Mediated Kidney Disease Market Share by Country (2016-2027)
Figure 49. Mexico APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Type (2016-2027)
Figure 53. Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Application (2016-2027)
Figure 54. Middle East & Africa APOL1 Mediated Kidney Disease Market Share by Country (2016-2027)
Figure 55. Turkey APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE APOL1 Mediated Kidney Disease Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Vertex Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 59. Ionis Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 60. Travere Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 61. ChemoCentryx Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 62. ZyVersa Therapeutics Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 63. GlaxoSmithKline Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 64. Novartis Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 65. Teva Pharmaceuticals Revenue Growth Rate in APOL1 Mediated Kidney Disease Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---